|
Indian Journal of Critical Care Medicine
Medknow Publications on behalf of the Indian Society of Critical Care Medicine
ISSN: 0972-5229 EISSN: 1998-359x
Vol. 9, Num. 1, 2005, pp. 42-46
|
Indian Journal of Critical Care Medicine, Vol. 9, No. 1, January-March, 2005, pp. 42-46
Review Article
Cerebral vasospasm: Aetiopathogenesis and intensive care management
Murthy T. V. S. P, Bhatia Maj Parmeet, Prabhakar Brig T.
Departments of Anesthesia and Intensive Care, Army Hospital (R&R), Delhi Cantt
Correspondence Address: Lt Col TVSP Murthy, Neuro Anesthesiologist and Intensivist, Departments of Anesthesia and Intensive Care, Army
Hospital (R&R), Delhi Cantt - 110010, India, E-mail: tvspmurthy@yahoo.com
Code Number: cm05008
Abstract Cerebral vasospasm is the prolonged, intense constriction of the larger conducting arteries in the subarachnoid space which are initially surrounded by subarachnoid clot. Significant narrowing develops gradually over the first few days after the aneurysmal rupture. The spasm usually is maximal in about a week's time following haemorrhage. Vasospasm is the one of the leading causes of death after the aneurysmal rupture along with the effect of the initial haemorrhage and latter rebleeding. The purpose of this article is to outline the importance in early diagnosis and aggressive treatment of this otherwise challenging clinical entity.
Keywords: Cerebral vasospasm, SAH, Intensive care
Introduction
Vasospasm is the prolonged, intense constriction of the larger conducting arteries in the subarachnoid space which are initially surrounded by subarachnoid clot. The narrowing of the vessels is best demonstrated by cerebral angiography. It is likely that spasmogens released from the breakdown of red blood cells trapped by a fibrin mesh in the abnormal environment of the subarachnoid space are responsible for causation of this vasospasm. Significant narrowing develops gradually over the first few days after aneurismal rupture,[1] and the vessel narrowing usually is not severe enough to cause ischemic symptoms for four days or so. The spasm is usually maximal about a week after the hemorrhage. Symptoms from infarction are also most common at around this time. The chance of the patients beginning to develop symptomatic infarction after two weeks on the basis of vasospasm is extraordinarily low or negligible.[2]
For patients in all neurologic grades following the aneurysmal rupture the chance is about 50-50 that significant angiographic vasospasm will develop. Between one-quarter and one-fifth of patients will get symptoms of delayed ischemia, and in between one-third and one-half there will be CT evidence of infarction due to cerebral vasospasm. Vasospastic infarction severe enough to cause death will occur in between one in twenty and one in six patients. Vasospasm is one of the leading causes of death after aneurysmal rupture along with the effect of the initial hemorrhage and later rebleeding.[3]
The more severe the initial hemorrhage and the larger the volume of subarachnoid clot, the more likely is the severity of diffuse vasospasm which will develop. For infarction to develop, there usually has to be an extreme degree of narrowing over a long segment of the vessels and a failure of collateral flow. Many other factors also play an important role which includes the circulating blood volume, cardiac output, blood pressure, intracranial pressure, and the age of the patient.
Time Course Vasospasm is almost never observed angiographically in the first three days following aneurysmal rupture. If it is seen on the first angiogram it probably indicates that the patient had a previously unsuspected bleeding episode prior to the one that brought the patient to medical attention. The vasospasm is maximal around seven to eight days following rupture and usually subsides by two or three weeks.[3] Aetiopathogenesis
The exact mechanism by which SAH induces arterial vasospasm continues to be a subject of considerable research and debate.
Arterial spasm most likely involves some alteration in the structure
of the vessel wall. Studies have shown that arterial vasospasm results
primarily from prolonged smooth muscle contraction. Hypertrophy, fibrosis,
and degeneration as well as other inflammatory changes in the vessel
wall are secondary effects that occur on a delayed basis. Extensive research
has shown that the big event that leads to the initiation of vasospasm
is the release of oxyhemoglobin (blood breakdown product). However, the
exact mechanism by which oxyhemoglobin induces vasoconstriction is unknown.
This mechanism appears to be a multifactorial process that involves the
generation of free radicals, lipid peroxidation and activation of protein
kinase C as well as phospholipase C and A2 with resultant accumulation
of diacylglycerol and the release of endothelin-1. These events appear
to create a positive feedback loop that, in turn, produces a tonic state
of smooth muscle contraction and inhibition of endothelium-dependent
relaxation. Serotonin, prostaglandins, catecholamines, histamine released
from the breakdown of platelets and erythrocytes are also implicated
as causative factors.
Classification Cerebral vasospasm is classified as either angiographic or symptomatic. Angiographic vasospasm is narrowing of a cerebral arterial territory, seen on angiography, without clinical symptoms. Symptomatic vasospasm is the clinical syndrome of cerebral ischemia associated with angiographically documented narrowing of a major cerebral territory.
Clinical Presentation Patient presents with progressive impairment in level of consciousness, especially after 72 to 96 hrs following SAH. There may be increase in focal defects. ECG shows q waves, ST elevation, peaked T waves, prolonged PR Interval and large U waves. Differential diagnosis include post operative bleed, electrolyte abnormality specially decreased serum sodium concentration, hypoxia, sepsis and hydrocephalus.
Diagnosis
Clinical
Progressive impairment in level of consciousness or increase in focal neurologic deficit occurring after four days of the bleeding episode should raise the suspicion of vasospasm. If surgery has been conducted early the differential diagnosis should include postoperative bleeding, swelling, electrolyte abnormality (particularly hyponatremia), hypoxia from respiratory complications, developing hydrocephalus, or sepsis. It is important not to use vasospasm as a catch-all explanation for any late deterioration.[3],[4]
Transcranial Doppler and Angiography
As the caliber of major conducting arteries is reduced, the velocity of blood going through them generally increases. A progressive increase in this velocity may be a harbinger of problem due to vasospasm. Patients who develop clinical evidence of ischemia from vasospasm often have mean velocities in the middle cerebral arteries of over 200 cm/s.[1],[4] Occasionally; the existence of intracranial hypertension will cause a spuriously low mean middle cerebral velocity. There are many exceptions to the linkage between increased velocities and ischemia; hence a close clinical correlation is required. Angiographic confirmation of severe diffuse vasospasm remains the gold standard.
Flow Studies: Xe-CT, PET, Isotopes
Several technologies currently are available for obtaining regional
cerebral blood flow estimates. The xenon-CT scan and positron emission
tomography (PET) scan provide excellent quantitative data but are not
generally available. Single photon emission tomography is generally more
commonly used, but the data are not quantitative.
Treatment
Prophylaxis
Early surgery permits the mechanical removal of fresh blood clot by suction and irrigation.[3],[5] Once the offending aneurysm has been secured by a clip it is possible to place tissue plasminogen activator within the subarachnoid space, either at the time of surgery or subsequently through catheters, to facilitate the early fibrinolysis of the clot, thus reducing the amount of decaying blood pressing against the arteries. This appears to be an effective way of preventing vasospasm. These fibrinolytic agents have a potential to cause bleeding by dissolving normal clot, so only patients at high risk of developing vasospasm should be chosen for this type of prophylaxis.
Calcium Antagonists
The one drug currently approved for use after subarachnoid hemorrhage
in North America is the calcium antagonist nimodipine. Its use was associated
with a reduced tendancy toward postaneurysmal cerebral infraction. Its
clinical effectiveness was not based on its ability to prevent or reverse
angiographically demonstrable vasospasm. Nimodipine can be used either
orally, intravenous or intra-arterial. The drug is potent and long lasting
than papavarine, is lipid soluble and crosses the blood brain barrier.[3],[6]
The treatment should ideally commence within 96 hours and to be instituted
up to 21 days either as infusion (1-2 mg/hr) or orally 60mg every 4 to
6 hourly to a maximum daily dose of 360 mg,[7],[8] the
role of Nicardipine a Calcium antagonist analogue is yet to be established.[8]
Endothelin Antagonists
Endothelin is the most potent naturally occurring vasoconstrictor.
It can be produced by vascular endothelium and smooth muscle cells. In
animal models, endothelin antagonists have been associated with reduced
incidence of chronic vasospasm following clot placement. Such compounds
have not yet gone to clinical trials. Nitric oxide has been tried with
no established results.
Induced Hypertension
While this therapeutic modality has never been subjected to prospective
clinical trial, it is nevertheless widely employed in the setting of
delayed ischemia after aneurysmal rupture.[1],[4],[6] All
experienced neurosurgeons have seen instances of dramatic reversal
of focal neurologic deficits by induction of arterial hypertension.
This
is usually done in association with normalization of the circulating
blood volume with fluid administration or transfusion. Very close clinical
observation is indicated when patients are receiving agents such as
dopamine or dobutamine in this setting. Xenon blood flow studies have
demonstrated
that in certain patients induced hypertension is associated with reduction
in regional cerebral blood flow. While such patients are undoubtedly
exceptional, this is an important caveat.
Hypervolemia
The avoidance of hypovolemia is perhaps more important than the institution of hypervolemia. The old days of intentional dehydration are gone forever. The optimal hematocrit varies from patient to patient, but it is probably reasonable to maintain it within the normal range. Crystalloid solutions are given to meet normal daily requirements. Glucose solutions are avoided. Human serum albumin is commonly used as a volume expander in dose of 1 g/kg per day divided in 4 to 6 doses/day, each administered over 30 to 60 min.
In critically ill patients or in those with compromised pulmonary function,
a Swan-Ganz catheter should be in place and appropriate monitoring used
to avoid circulatory overload and pulmonary edema, as well as to ensure
the optimization of cardiac output.[1],[2],[5]
Angioplasty
If the patient is in imminent danger from severe diffuse vasospasm
refractory to hypertension and hypervolemia, these spastic arterial
segments may be forcibly dilated by means of small, sausage-shaped
balloons placed through intra-arterial catheters.[9],[12],[13],[14] In
expert hands, this is associated with the permanent reversal of vasospasm
and clinical improvement in one-half to two-thirds of patients. There
is a serious risk of arterial rupture, hence the procedure should be
restricted to experienced interventional neuroradiologists on the advice
of experienced clinicians.[1],[4]
Intraarterial Papavarine
The proximal segment of the anterior cerebral artery, the posterior
cerebral arteries, and distal middle cerebral arteries are not amenable
to balloon dilatation because of size or angle of take-off. The instillation
over several hours of high concentrations of intra-arterial papavarine
has been associated with reversal of spasm in some cases.[4],[10] There
has been a tendency for spasm to recur, and the infusion may have to
be repeated, but it is sometimes associated with clinical improvement.[11],[15] Again,
this is not a therapy to be undertaken lightly or before the failure
of more conventional means.[17],[18],[19]
Other pharmacologic interventions
The intrathecal administration of recombinant tissue plasminogen activator (rtPA) has been shown to dissolve subarachnoid clots, thereby preventing vasospasm in humans. The use of rtPA in human trial has reduced the severity of angiographic vasospasm and improved the clinical neurologic grade of the patients. The other agents tried to varying results are Streptokinase and Urokinase. Tirilazad, a 21 amino steroid glucocorticoid with anti inflammatory properties has shown promising results and stays as a new drug with great expectations, the results of which require authentication.
Alternatively, the super-selective intra-arterial infusion of papavarine[19],[20],[21],[22],[24] (2
mg over 10 s) has been shown to be effective in dilating spastic distal
vessel not accessible to angioplasty techniques.[23],[25]
Intrathecal sodium nitroprusside was recently suggested as a treatment
for cerebral ischemia in patients with severe, medically refractory
vasospasm after sub arachnoid haemorrhage (10 to 40 mg single dose
and 2 to 8 mg/hr as infusion)
Alprostadil - Prostaglandin E1 may be of value in the treatment of
vasospasm. The efficacy is yet to be established. Intra arterial
Nimodipine, has also been tried, but it does not work as well as papavarine,
though
it has a more long lasting effect. Nitroglycerine used intra arterial,
has shown some success.
The general measures of good intensive care, proper ventilation and
provision of optimal nutrition promote faster recovery and helps
in better outcome.
Conclusion
Vasospasm is a clinical challenge. Timely diagnosis and aggressive treatment
are essential goals for a better outcome, which otherwise carries a high
morbidity and mortality.
References
1. | Awad IA, editor. Current management of cerebral aneurysms. Neurosurgical Topics, AANS, 1993. p. 327. Back to cited text no. 1 |
2. | Fox JL. Intracranial Aneurysms. New York: Springer-Verlag; 1983. p. 1462. Back to cited text no. 2 |
3. | Weir B. Aneurysms affecting the nervous system. Baltimore: Williams & Wilkins; 1987. p. 671. Back to cited text no. 3 |
4. | Carter LP, et al, editors. Neurovascular Surgery, New York: McGraw-Hill; 1994. p. 1446. Back to cited text no. 4 |
5. | Kassell NF, et al. The international cooperative study on the timing of aneurysm surgery. Part I. Overall management results. J Neurosurg 1990;73:18. Back to cited text no. 5 [PUBMED] |
6. | Ratcheson RA, Wirth FP. Ruptured Cerebral Aneurysms, Perioperative management in Cerebral Aneurysmal Neurosurgery. Baltimore: Williams and Wilkins; 1994. p. 208. Back to cited text no. 6 |
7. | Haley EC, et al. A randomized trial of two doses of Nicardipine in aneurismal subarachnoid haemorrhage. A report of the cooperative aneurysm study. J Neurosurg 1994. p. 80. Back to cited text no. 7 |
8. | Raabe A, Zimmermann M, Setzer M, Vatter H, et al. Neurosurgery 2002;50:1006-13. Back to cited text no. 8 [PUBMED] [FULLTEXT] |
9. | Brothers MF, Holgate RC, Intracranial angioplasty for treatment of vasospasm after subarachnoid hemorrhage: Technique and modifications to improve branch access. AJNR 1990;11:239-47. Back to cited text no. 9 |
10. | Clouston JE. Numaguchi Y. Zoarski GH. Aldrich EF. Simard JM. Zitnay KM. Intraarterial papaverine infusion for cerebral vasospasm after subarachnoid hemorrhage. AJNR 1995;16:27-38. Back to cited text no. 10 |
11. | Clyde BL, Firlik AD, Kaufmann AM, Spearman MP, Yonas H. Paradoxical aggravation of vasospasm with papaverine infusion following aneurysmal subarachnoid hemorrhage: Case report. J Neurosurg 1996;84:690-5. Back to cited text no. 11 [PUBMED] |
12. | Eskridge JM, Newell DW, Mayberg MR, Winn HR. Update on transluminal angioplasty of vasospasm. Perspect Neurol Surg 1990;1:120-6. Back to cited text no. 12 |
13. | Eskridge JM, Newell DW, Winn HR. Endovascular treatment of vasospasm. Neurosurg Clin N Am 1994;5:437-47. Back to cited text no. 13 [PUBMED] |
14. | Higashida RT, Halbach VV, Dowd CF, et al. Intravascular balloon dilatation therapy for intracranial arterial vasospasm: Patient selection, technique and clinical results. Neurosurg Rev 1992;15:89-95. Back to cited text no. 14 [PUBMED] |
15. | Kaku Y. Yonekawa Y. Tsukahara T. Kazekawa K. Superselective intra-arterial infusion of papaverine for the treatment of cerebral vasospasm after subarachnoid hemorrhage. J Neurosurg 1992;77:842-7. Back to cited text no. 15 |
16. | Kallmes DF, Jensen ME, Dion JE. Infusing doubt into the efficacy of papaverine. AJNR 1997;18:263-4. Back to cited text no. 16 [PUBMED] [FULLTEXT] |
17. | Kassell NF, Helm G, Simmons N, Phillips CD, Cail WS. Treatment of cerebral vasospasm with intra-arterial papaverine. J Neurosurg 1992;77:848-52. Back to cited text no. 17 [PUBMED] |
18. | Livingston K. Guterman LR. Hopkins LN. Intraarterial papaverine as an adjunct to transluminal angioplasty for vasospasm induced by subarachnoid. Am J Neuroradiol 1993;14:346-7. Back to cited text no. 18 |
19. | Marks MP, Steinberg GK, Lane B. Intraarterial papaverine for the treatment of vasospasm. AJNR 1993;14:822-6. Back to cited text no. 19 [PUBMED] |
20. | Mathis JM, DeNardo A, Jensen ME, Scott J, Dion JE. Transient neurologic events associated with intraarterial papaverine infusion for subarachnoid hemorrhage-induced vasospasm. AJNR 1994;15:1671-4. Back to cited text no. 20 [PUBMED] |
21. | Mathis JM, Jensen ME, Dion JE. Technical considerations on intra-arterial papaverine hydrochloride for cerebral vasospasm. Neuroradiology 1997;39:90-8. Back to cited text no. 21 [PUBMED] [FULLTEXT] |
22. | McAuliffe W, Townsend M, Eskridge JM, Newell DW, Grady S, Winn HR. Intracranial pressure changes induced during papaverine infusion for treatment of vasospasm. J Neurosurg 1995;83:430-4. Back to cited text no. 22 |
23. | Takahashi A, Yoshoto T, Mizoi K, et al. Transluminal balloon angioplasty for vasospasm after subarachnoid hemorrhage. In: Cerebral Vasspam, edited by Sano K, Takakura K, Kassell NF, Sasaki T. Tokyo: U Tokyo Press; 1990. p. 429-32. Back to cited text no. 23 |
24. | Tsukahara T, Yoshimura S, Kazekawa K, Hashimoto N. Intra-arterial papaverine for the treatment of cerebral vasospasm after subarachnoid hemorrhage. Autonomic Nervous System. 1994;49 Suppl:S163-6. Back to cited text no. 24 [PUBMED] |
25. | Zubkov YN, Nikiforov BM, Shustin VA. Balloon catheter technique for dilatation ofconstricted cerebral arteries after aneurysmal SAH. Acta Neurochir (Wien) 1984;70:65-79. Back to cited text no. 25 [PUBMED] |
Copyright 2005 - Indian Journal of Critical Care Medicine
|